Summary & Overview
HCPCS J2690: Injection, procainamide HCl, up to 1 gm
HCPCS Level II code J2690 denotes injection of procainamide HCl, billed per package or unit (up to 1 gram). Procainamide is an antiarrhythmic medication used in acute management of certain cardiac arrhythmias, and the HCPCS designation standardizes reporting of the drug supply component for billing and reimbursement. Nationally, clear identification of parenteral drug codes like J2690 affects facility charge capture, payer adjudication, and inventory accounting for high-acuity services.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context for the drug formulation and typical sites of service, plus a concise guide to what to expect when billing this supply code across major payers. The publication highlights benchmarks and payer coverage patterns where available, summarizes relevant billing considerations for facility-administered parenteral drugs, and flags common administrative elements that influence claim processing.
This summary is intended for revenue cycle, compliance, and clinical staff seeking a national perspective on how HCPCS Level II code J2690 is used to represent procainamide injection in billing workflows.
Billing Code Overview
HCPCS Level II code J2690 represents an injectable formulation of procainamide hydrochloride, billed per unit of up to 1 gram. This code describes a pharmaceutical service: administration of a specific antiarrhythmic medication supplied as an injection.
-
Service type: Medication injection (parenteral drug service)
-
Typical site of service: Hospital inpatient, hospital outpatient department, emergency department, or other settings where intravenous or intramuscular antiarrhythmic therapy is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to the emergency department or inpatient unit with symptomatic ventricular arrhythmia (for example, sustained ventricular tachycardia) or life-threatening supraventricular arrhythmias unresponsive to first-line therapy. The cardiology team evaluates rhythm strips, vital signs, electrolytes, and drug history. After indication is confirmed and contraindications (e.g., advanced heart block without pacemaker, allergy to procainamide) are excluded, the provider orders intravenous procainamide for acute arrhythmia suppression. Medication is prepared in pharmacy or at bedside, weight-based dosing is confirmed, and continuous cardiac monitoring is initiated. The drug is administered as an intravenous injection or infusion per institutional protocol with frequent ECG and hemodynamic monitoring; dose adjustments or discontinuation occur for hypotension, QRS widening, or arrhythmia termination. Documentation includes indication, informed consent when required, exact dose (J2690 describes up to 1 gm), route, time, patient response, monitoring data, and any adverse events. Typical sites of service are emergency department, inpatient ward, or monitored procedure areas within hospitals.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Provider's usual, customary, and reasonable (UCR) service | Use when this is the primary service provided by the physician as billed. |